No profile data available.
Lipella Pharmaceuticals Inc. (LIPO) is a healthcare company in the urinary system treatment drugs industry, based in Pittsburgh, United States, with about 5 full-time employees.
It reported revenue of $536,357 for fiscal year 2024, up 19.3% from fiscal year 2023, and net income of -$5.02 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0, down 100.0% from a year before. Its market capitalization was $2,310 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
Lipella Pharmaceuticals reported $536,357 in revenue for fiscal year 2024, up 19.3% from $449,617 in fiscal year 2023. In Q3 2025 revenue was $0.
$2,310 as of October 8, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Tvardi Therapeutics, Inc. (TVRD), Nymox Pharmaceutical Corporation (NYMXF), ZyVersa Therapeutics, Inc. (ZVSA).